Novo Nordisk A/S (NVO) Reaches New 12-Month Low at $45.36
Novo Nordisk A/S (NYSE:NVO) hit a new 52-week low on Friday . The stock traded as low as $45.36 and last traded at $45.79, with a volume of 2,863,145 shares changing hands. The stock had previously closed at $46.34.
Several equities research analysts recently weighed in on the stock. Citigroup Inc. reissued a “buy” rating on shares of Novo Nordisk A/S in a research report on Wednesday, August 3rd. Zacks Investment Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Monday, July 4th. Goldman Sachs Group Inc. downgraded shares of Novo Nordisk A/S from a “conviction-buy” rating to a “buy” rating in a research report on Tuesday, June 28th. Bank of America Corp. downgraded shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Monday, August 8th. Finally, Morgan Stanley downgraded shares of Novo Nordisk A/S from an “overweight” rating to an “equal weight” rating in a research report on Thursday. Four analysts have rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $63.50.
The company has a market capitalization of $116.16 billion and a price-to-earnings ratio of 21.44. The company has a 50 day moving average price of $50.68 and a 200-day moving average price of $53.54.
The business also recently announced a dividend, which was paid on Tuesday, August 23rd. Shareholders of record on Monday, August 15th were paid a $0.326 dividend. The ex-dividend date of this dividend was Thursday, August 11th.
Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.